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ABSTRACT 
Background: Intradialytic hypotension is a potential complication experienced by patients with 
end-stage renal disease who receive hemodialysis. This complication occurs during the dialysis 
treatment in 15-30% of all treatments. The multiple comorbidities that exist in hemodialysis 
patients predispose them to recurrent intradialytic hypotension episodes. Recurrent intradialytic 
hypotensive episodes can result in negative short-term and long-term clinical consequences. 
Short-term consequences include complications such as ischemic events (e.g., heart attacks, 
strokes), clotting of patient dialysis access, or heart rhythm abnormalities. Long-term 
consequences include end-organ damage, increased cardiovascular morbidity, and a higher 
mortality rate. Problem Statement: Available nursing interventions used to treat intradialytic 
hypotension such as decreased dialysis fluid temperature, changes in the calcium and sodium 
concentrations in the dialysis fluid and oral medication have limited success. Another existing 
technological intervention called blood volume monitoring shows greater potential success but is 
currently underutilized. Purpose: The purpose of this literature review is to synthesize current 
literature on blood volume monitoring technology used to prevent intradialytic hypotension in 
hemodialysis patients. Methods: A literature review was conducted analyzing pertinent research 
articles published in the last ten years, in addition to seminal articles. Seventeen articles were 
retrieved and analyzed that met criteria. Results: Fourteen of the seventeen research studies 
reached a consensus on the successful use of blood volume monitoring to decrease intradialytic 
hypotension and the related symptoms. Conclusion: Results of the literature review support the 
use of blood volume monitoring technology as an effective nursing intervention to prevent 
intradialytic hypotension in hemodialysis patients. 
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INTRODUCTION 
Intradialytic hypotension (IDH) is an incommodious and pernicious side effect seen in 
many patients with end-stage renal disease (ESRD) who receive hemodialysis (HD). IDH can 
result in serious complications, including ischemic events, vascular access thrombosis, 
dysrhythmias, and mesenteric venous infarction (Kidney Dialysis Outcomes Quality Initiatives 
Workgroup [KDOQI], 2005). Other long-term complications may include fluid volume overload 
due to fluid resuscitation, left ventricular hypertrophy (LVH), and interdialytic hypertension 
(KDOQI Workgroup, 2005). Nurses are at the forefront of dialysis care and are in a unique 
position to recognize early signs of IDH and intervene. 
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SIGNIFICANCE   
IDH occurs in 15%-30% of HD treatments (Reilly, 2014).  The incidence increases to 
50% with predisposed ESRD individuals, with comorbidities like diabetes and cardiac anomalies 
(Reilly, 2014).     
Intradialytic systolic blood pressure (SBP) of <100 mm Hg, with a predialysis SBP of 
≥160 mm Hg in patients who receive HD is associated with increased mortality (Reeves & Mc 
Causland, 2018). Patients with intradialytic SBP of <90 mm Hg with a predialysis SBP of <160 
mm Hg have the same increased risk of mortality (Reeves & Mc Causland, 2018). Van Buren 
and Inrig (2017) noted that the risk of death is greater among patients with a decrease in SBP of 
≥30 mm Hg from pre- to post-dialysis. Alternatively, Reeves and Causland (2018) found that 
absolute blood pressure declines (30 mm Hg from pre-dialysis blood pressure) had no 
association with mortality rates, suggesting that there is a threshold below which end-organ 
hypoperfusion occurs. The higher the frequency of IDH occurrence, the greater the mortality rate 
(Reeves & Mc Causland, 2018).  
Transient oxygen deprivation to myocardial tissue from IDH causes prolonged left 
ventricular (LV) systolic dysfunction, also called myocardial stunning (Ok, Levin, Asci, Chazot, 
Tox, & Ozkahya, 2017).  Although ischemic episodes of short duration may not cause cardiac 
cell death, they may eventually lead to permanent damage to LV function (Ok et al., 2017). 
During dialysis, patients without significant coronary artery disease (CAD) show LV wall 
abnormalities and decreased blood flow to cardiac muscle tissue (Ok et al., 2017).  
Dialysis-related LV systolic dysfunction is linked to decreased LV ejection fraction, 
higher endotoxin level, and increased risk of mortality (Ok et al., 2017). According to Dasselaar 
et al. (2009), non-diabetic patients who underwent dialysis with a minimal ultrafiltration (UF) 
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had a decrease in myocardial blood volume within the first 30 minutes of treatment, without 
substantial blood pressure or blood volume changes. IDH has been independently linked to 
cardiac mortality, myocardial infarction, and hospitalization for heart failure and volume 
overload (Reeves & Mc Causland, 2018).  
Intradialytic blood pressure declines are associated with decreased blood flow to the 
middle cerebral artery, leading to hypoperfusion of brain tissue (Reeves & Mc Causland, 2018). 
Consequently, higher incidence of IDH is associated with a decrease in frontal brain area to 
intracranial frontal space (Reeves & Mc Causland, 2018) and cognitive decline (Chou, Kalantar-
Zadeh & Mathew, 2017). MRI findings of patients with IDH include cerebral infarcts, atrophy, 
and leukoaraiosis (caused by the deprivation of oxygen and is a risk factor for dementia and 
strokes) (Chou, Kalantar-Zadeh, & Matthew, 2017).  
Hemodynamic instability with IDH also causes the gut to displace endotoxins across the 
intestinal lining causing bowel edema and hypoperfusion (Chou et al., 2017).  Patients on HD 
have high endotoxin levels that aid in creating pro-inflammatory processes that lead to 
malnutrition, wasting, and poor cardiovascular outcomes (Chou et al., 2017). This increase in 
endotoxin levels is due, in part, to poor mesenteric blood flow during dialysis (Chou et al., 
2017).  
Patients with greater decline in SBP had two times the risk of developing thrombosis in 
their vascular access (i.e., arteriovenous fistula, arteriovenous graft, or central venous catheter) 
during follow-up (Reeves & Mc Causland, 2018). Patients with an IDH frequency of >29% had 
twice the risk of developing thrombosis in their vascular access compared to patients without 
IDH (Ok et al., 2017).  
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PROBLEM STATEMENT   
Although dialysis technology has improved in the past decade, the frequency of IDH  
remains unchanged (Reilly, 2014). Many HD patients continue to experience IDH, despite the 
use of current interventions, such as decreased dialysate temperature, sodium and calcium 
modeling, and the use of midodrine (KDOQI Workgroup, 2005).  IDH contributes to long-term  
complications such as end-organ damage, increased cardiovascular morbidity, and a greater  
mortality rate (Reilly, 2014).  Given the substantial adverse complications associated with IDH  
including increased morbidity and mortality, a currently existing, but underutilized, dialysis  
technology intervention merits further consideration (Reilly, 2014). The use of blood volume  
monitoring (BVM) is one such technological advancement that nurses can utilize to prevent IDH.   
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PURPOSE 
The purpose of this literature review is to synthesize the current literature on BVM with 
biofeedback UF technology used to prevent IDH in HD patients.  
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BACKGROUND 
Intradialytic Hypotension  
IDH is an intradialytic complication where blood pressure is markedly decreased in 
response to fluid volume and urea removal. IDH is defined as a decrease in SBP ≥ 20 mm Hg or 
a decrease in mean arterial pressure (MAP) of ≥ 10 mm Hg during a dialysis treatment (KDOQI 
Workgroup, 2005). Symptoms accompanying IDH include nausea, vomiting, muscle cramps, 
and dizziness (KDOQI Workgroup, 2005). Consequently, the treatment of IDH-related 
symptoms, after they occur, may lead to suboptimal dialysis treatments and affect the Kt/V (the 
laboratory value reflecting the toxin removal from the blood). The Kt/V value reflects the 
effectiveness of dialysis treatment and indicates whether changes in dialysis prescription are 
merited (KDOQI Workgroup, 2005). Established measures used to treat IDH when it occurs 
currently include decreasing dialysate temperature, sodium and calcium modeling, and the use of 
pharmacologic agents, such as midodrine (ProAmatine) (KDOQI Workgroup, 2005). There is no 
established measure to prevent IDH in clinical practice.  
Risk Factors for IDH  
Non-modifiable risk factors for IDH include older age (>60 years of age) (KDOQI, 
2005), female gender, Hispanic ethnicity, and increased number of years on dialysis (Chou et al., 
2017). Patients with the following comorbidities are predisposed to IDH: diabetes mellitus (DM), 
CAD, systolic dysfunction, LVH, and increased cardiac enzymes (Chou et al., 2017). IDH risk 
factors that can be modified with patient health behavior change include hyperphosphatemia, 
antihypertensive medication usage, eating a meal before hemodialysis treatments, increased body 
mass index, decreased albumin levels, and interdialytic fluid weight gain (Chou et al., 2017). 
Dialysis prescription of low sodium dialysate (fluid used to clean blood during dialysis) (≤ 135 
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mmol/L) is associated with increased frequency of IDH, while higher dialysate calcium is 
associated with decreased rate of IDH (Chou et al., 2017).  
Pathophysiology of IDH  
To address how IDH occurs, the different factors that affect blood pressure must be 
considered. Blood pressure is determined by blood volume, systemic vascular resistance, and 
cardiac output (Santos, Peixoto, & Perazella, 2012). Hemodialysis may cause impairment in 
more than one of these factors, affecting the body’s normal compensatory mechanism (Santos et 
al., 2012).  
High UF rates (the rate at which the blood is cleaned, and fluid is removed during 
dialysis) is often higher than the patient’s plasma volume (Agarwal, 2012; Santos et al., 2012).  
Elevated UF rates, combined with decreased extracellular osmolality, cause a drastic reduction in 
plasma volume (Reeves et al., 2018; Santos et al., 2012). These combined processes lead to 
reduced plasma refilling and hemodynamic instability (Reilly, 2014; Santos et al., 2012). The 
effects are greater in patients with impaired vascular compliance and blood redistribution (Santos 
et al., 2012).   
Vasoconstriction of the splenic and cutaneous circulation occurs to compensate for lack 
of plasma refilling, leading to decreased venous pooling (Reeves et al., 2018; Santos et al., 
2012). This mechanism redistributes blood to the central blood compartment to support adequate 
cardiac filling and cardiac output (Chou et al.,2017; Santos et al., 2012). This compensatory 
process of blood redistribution is impaired in ESRD patients due to their comorbidities (Reilly, 
2014; Santos et al., 2012).  Increased core temperatures during dialysis cause the blood to 
redistribute from the central circulation to the skin (to reduce core temperature), further 
decreasing central blood volume (Santos et al., 2012).   
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Patients with DM, structural heart disease, and the elderly are afflicted with autonomic 
dysfunction, decreased function of cardiopulmonary receptors, and diminished arterial 
pressoreceptors (Reilly, 2014; Santos et al., 2012). Patients at greater risk of IDH were identified 
as having impaired resting baroreflex sensitivity (Agarwal, 2012; Santos et al., 2012). The 
uremic component of autonomic dysfunction is linked to the development of IDH (Agarwal, 
2012; Santos et al., 2012). There is also an imbalance between vasoconstrictor (less endothelin-
1) and vasodilator (elevated nitric oxide) processes supporting vasodilation which predisposes 
patients to IDH (Santos et al., 2012).   
Some ESRD patients may have large amounts of adenosine production from oxygen-
deprived tissues during UF (Santos et al., 2012). Elevated adenosine is believed to decrease 
blood pressure by reducing norepinephrine secretion and stimulating vasodilation and venous 
blood pooling (Bradshaw, 2014; Santos et al., 2012).  Vasopressin release in some IDH patients 
is deficient and escalates hemodynamic instability (Santos et al., 2012).  
Patients in HD have circulating endotoxemia (immune marker indicating low grade 
inflammation), which is associated with increased relative IDH (Agarwal, 2012; Santos et al., 
2012). ESRD patients with any of the disorders (impaired resting baroreflex sensitivity, 
increased adenosine production, or endotoxemia) cannot compensate by increasing vascular 
resistance. Their inability to compensate breeds a perfect environment for IDH to occur (Chou et 
al., 2017; Santos et al., 2012).   
Another underlying structural cardiac abnormality that frequently results in IDH is LVH 
(Chou et al., 2017; Santos et al., 2012). In patients with ESRD, LVH is caused by long-standing 
hypertension, chronic volume overload, severe anemia, and arteriovenous shunts (Santos et al., 
2012). LVH is the most prevalent cardiac anomaly in ESRD patients (Santos et al., 2012).  
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LVH is frequently associated with systolic or diastolic cardiac dysfunction, which may 
increase the propensity of patients to develop IDH (Chou et al., 2017; Santos et al., 2012). 
Cardiac output decreases when intravascular blood volume, central blood volume, and cardiac 
preload are reduced. The diminished cardiac output, as seen with systolic and diastolic 
dysfunction, can precipitate a drop in blood pressure and lead to IDH occurrence (Santos et al., 
2012).  
Current IDH Interventions  
There are four interventions currently in practice to treat IDH: decreasing dialysate 
temperature, sodium modeling, calcium modeling, and pharmaceutical intervention. These 
interventions will be described in greater detail.  
Dialysis Interventions Used to Treat IDH When It Occurs.  
Decreasing Dialysate Temperature.  
During HD, it is common for the core body temperature to increase (due to heat load 
from the dialysis machine or secondary to volume removal) (KDOQI Workgroup, 2005).  Once 
core temperatures reach a critical level (level at which the body’s homeostatic mechanism are 
triggered), peripheral dilation occurs (Reilly, 2014), leading to an increased risk of IDH (KDOQI 
Workgroup, 2005). Lower dialysate temperature (decreasing dialysate temperature lower than 
the patient’s core temperature) compared with standard dialysate temperature (37° C) is thought 
to reduce the frequency and intensity of symptomatic IDH (KDOQI Workgroup, 2005). Lower 
dialysate temperature is related to a decline in LV regional wall abnormalities, improved 
peripheral vasopressor reactions, and an increase in baroreceptor sensitivity (Reilly, 2014). The 
patients may complain of feeling cold with this intervention (Reilly, 2014) and patients are at an 
increased risk of diminished Kt/V (Larkin, Reviriego-Mendoza, Usvyat, Kotanko, & Maddux, 
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2017). Many dialysis patients are already hypothermic, making them inadequate candidates for 
this intervention (Reilly, 2014).  This treatment modality is only useful on the short-term basis 
(Larkin et al., 2017). Larkin et al. (2017) did a literature review on the effectiveness of 
decreasing dialysate temperature and found that there is a lack of studies to suggest the 
effectiveness of decreasing dialysate temperature for the long-term prevention of IDH.  
Sodium Modeling.  
Sodium modeling is an intervention in which the sodium dialysate concentration is higher 
at the beginning of dialysis and decreases gradually towards the end of the dialysis treatment 
(KDOQI Workgroup, 2005). Nurses preset the HD machine according to a physician’s or nurse 
practitioner’s orders before the start of the HD treatment to carry out sodium modeling 
automatically. Sodium profiling prevents IDH by increasing extracellular fluid sodium levels at 
the time of peak UF, which helps shift water from the intracellular space to the extracellular 
space and improves venous refill and prevents the Bezold-Jarisch reflex (a cardiovascular 
mechanism activated in response to decreased oxygenation levels to myocardial tissue that leads 
to vasodilation, bradycardia, and hypotension [Johnson, 2013, p. 215]) (KDOQI Workgroup, 
2005).  
Sodium profiling also ameliorates the urea equilibrium between the intracellular fluid and 
extracellular fluid (KDOQI Workgroup, 2005). Using higher levels of dialysate sodium 
concentrations during the start of dialysis necessitates lower than mean dialysate sodium 
concentration towards the end of treatment (Reilly, 2014).  
During the period when lower sodium concentration is implemented, the patients are at a 
higher risk of IDH (Reilly, 2014). The ramification of sodium modeling is a positive sodium 
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balance in the patient at the end of dialysis which often leads to elevated blood pressure, 
increased thirst, and increased interdialytic weight gain (Chou et al., 2017).  
Calcium Modeling.  
Low calcium dialysate is associated with decreased LV contraction and hypotension 
(KDOQI Workgroup, 2005). Associations between low calcium baths and low blood pressure 
affect IDH-prone patients and non-IDH prone patients (KDOQI Workgroup, 2005). Increased 
calcium concentrate in dialysate provides increased stroke volume, increased SBP, and elevated 
serum calcium concentration (Reilly, 2014).   
In a small subgroup of predisposed IDH individuals, Reilly (2014) found that changes in 
MAP were modest and did not result in a significant decrease in IDH occurrence. Higher calcium 
dialysates, for example a 3.5 mEq/L calcium bath, can cause hypercalcemia and significantly 
increase the risk of decreased bone turnover (KDOQI Workgroup, 2005). Given the minimal 
effects of calcium modeling on IDH and the increased risk of positive calcium balance, changing 
calcium dialysate prescription is not commonly used (Reilly, 2014).  
Pharmaceutical Intervention.  
Midodrine (ProAmatine) is a selective alpha one agonist and has an off-label use for IDH 
prevention (Chou et al., 2017).  The use of Midodrine is associated with a decrease in the 
severity of symptoms related to IDH (KDOQI Workgroup, 2005). It prevents IDH by preserving 
the central blood volume and cardiac output with a marginal increase in peripheral vascular 
resistance (KDOQI Workgroup, 2005). Dialysis patients self-administer this medication 30 
minutes before the initiation of HD, as this medication is not available to nurses in outpatient 
dialysis clinics (Chou et al., 2017). A second dose is administered halfway through the treatment, 
if needed (Reilly, 2014). The peak action of the drug is one hour after administration, and it is 
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dialyzed out of the body. Thus, the half-life of the medication on dialysis is three hours (Reilly, 
2014). Some patients experience unpleasant side effects from midodrine such as pruritus, supine 
hypertension, and goosebumps, which may discourage use of the medication (Chou et al., 2017). 
The side effect of supine hypertension occurs in less than 10% of patients, but, warrants 
cessation of the medication for patients who experience this side effect (KDOQI Workgroup, 
2005).  
Dialysis Technological Intervention Used to Prevent IDH. 
Blood Volume Monitoring. 
  A technological device used to monitor blood volume is one in which the patient’s 
relative blood volume (RBV) is recorded in real time throughout the HD treatment (Bradshaw, 
2014; Micklos, 2013). These devices non-invasively monitor relative blood volume, hematocrit, 
and oxygen saturation (Gul, 2016). Some newer dialysis machines come equipped with a blood 
volume monitor, however, one can be added to the dialysis machine (e.g., Crit-line monitor) 
(Micklos, 2013).  
A Crit-line monitor measures RBV based on hematocrit (Micklos, 2013). It measures 
hematocrit concentration using photo-optical technology, a sensor emitting a light beam through 
the blood chamber, the red blood cells reflect the light, the dispersion of the light change due to 
fluctuations in hematocrit concentrations, and these values are recorded (Micklos, 2013). 
In machines equipped with a blood volume monitor, the RBV is tracked in response to 
changes in hematocrit levels. Specific prompts advise the nurse when the UF rate is less than, 
equal to, or greater than the plasma refill rate (Bradshaw, 2014). The fluid removal progress is 
also displayed on the dialysis machine screen (Bradshaw, 2014). The RBV trends provide more 
information on the patient’s hemodynamic stability rather than the absolute value at any point in 
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time during the dialysis treatment (Bradshaw, 2014). The greater the slope of RBV, the greater 
the fluid removal rate compared to the plasma refill rate, which does not allow for safer removal 
of fluid volume and precipitates IDH (Bradshaw, 2014).  
Over successive HD treatments, critical RBV (threshold in which the plasma refill rate is 
greater than the fluid removal rate) levels are determined by the nephrology team for each patient 
(Bradshaw, 2014). Once the machine is programmed by the dialysis nurse based on each 
patient’s critical RBV, the biofeedback mechanism will inform staff when critical RBV is 
achieved and will automatically adjust the UF rate accordingly, thus preventing IDH (Bradshaw, 
2014).  
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METHODS 
A literature review was conducted analyzing the articles published in the last ten years, in 
addition to seminal articles. CINAHL, Cochrane Central Register of Controlled Trials, Cochrane 
Database of Systematic Reviews, Medline, and PsychINFO were utilized to identify journals 
published in nursing. Search terms included: (a) dialysis, (b) intradialytic, (c) dialysis patients, 
(d) ultrafiltration (and UF, modeling, profiling, monitoring, and biofeedback), (e) hypoten* (and 
low blood pressure), and (f) blood volume. The population was limited to patients ≥18 years old. 
The search was limited by those published in English. Duplicate articles were excluded.  
Each article was evaluated individually to determine the relevancy of using BVM to 
determine the UF rate by a title and abstract review. Hierarchy of evidence was considered to 
assess the reliability and validity of each article. An evidence table was developed to organize 
the journals and significant findings. A synthesis of the research is presented as a thesis. 
By using the search criteria and limiters, a total of 85 journal articles were retrieved. 
After the title review, 43 articles went under an abstract review, resulting in 12 articles that met 
the inclusion and exclusion criteria. Five seminal articles were included, accruing a total of 17 
articles analyzed in this literature review.  
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FINDINGS 
The literature review demonstrated a consensus that BVM biofeedback technology not 
only decreased the frequency of IDH but also offered other benefits during treatment. The 
analyzed studies included randomized control trials (7), nonrandomized control trials (1), 
prospective studies (5), systematic review and metanalysis (1), pilot study (1), prospective audit 
(1), and descriptive clinical evaluation (1). The findings are divided into two sections based on 
the relevant themes found in the review: 1. IDH & intradialytic morbid events (IME) and 2. 
adequacy & target weight. 
Intradialytic Hypotension & Intradialytic Morbid Events    
BVM technology demonstrated a reduction in IMEs, which are described as symptomatic 
hypotensive episodes, muscle cramps, nausea, dizziness, headache vomiting, unconsciousness, or 
other adverse symptoms requiring nursing intervention (Gabrielli et al., 2009).  
Winkler et al. (2008) found similar results in a descriptive clinical evaluation of diabetic 
patients with cardiac disease. BVM corrected cardiac function and reduced the pure water 
overload triggered by diabetes and intermittent hyperglycemia (Winkler et al., 2008).  The 
improved refilling rates significantly increased ejection fraction and nearly normalized left 
ventricular mass index (p < 0.05) (Winkler et al., 2008). Clinically, the use of BVM significantly 
reduced IDH (p < 0.01) and muscle cramps (p < 0.01) (Winkler et al., 2008).   
In a prospective study, McIntyre et al. (2003) showed that treatments using BVM had an 
IME reduction of 1.5% during HD treatments. McIntyre et al. (2003) identified that BVM 
technology reduced the incidence of symptomatic and asymptomatic IDH in the patient 
population prone to IDH and those not prone to IDH (p < 0.001).  
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In a randomized crossover study, Veljančic et al. (2011) further explained that although 
not all patients benefit from BVM and blood temperature monitoring (BTM), both account for 
more than 70% of patients experiencing fewer IMEs compared to standard hemodialysis (SHD) 
(p = 0.024). Veljančic et al. (2011) observed that the combination of BVM and BTM contributed 
to a 45% reduction in IMEs compared to non-isothermal HD. The results were partially 
attributed to the blood volume control mechanism rather than the BTM (Veljančic et al., 2011).   
Steurer et al. (1996) conducted a single sample nonrandomized trial to study five patients 
for a total of 106 dialysis treatment sessions. The patient sample underwent a control session 
with SHD alternating with an experimental session, in which BVM was the independent 
variable. The authors found that blood pressure was not a predictor of intradialytic morbidity. 
Other symptoms (i.e., muscle cramping, lightheadedness, and nausea) correlated with 
hypovolemia, although intradialytic symptoms were not constantly reflected by blood pressure 
changes (Steurer et al., 1996). The variability in intradialytic morbid events and hypotension was 
due to other factors that affected blood volume shifts, including predialysis hydration status, 
physical exertion, mental state, and neurohormonal compensatory mechanisms (Steurer et al., 
1996). Monitoring blood volume demonstrated that it was more beneficial than blood pressure 
monitoring in preventing IDH related to hypovolemia (p = 0.02) (Steurer et al., 1996). Every 
subject who experienced IDH and intradialytic symptoms did so at specific hematocrit thresholds 
(Steurer et al., 1996). This hematocrit threshold was consistent for each patient in subsequent 
treatments (Steurer et al., 1996). Sessions complicated by IMEs resulted from exceeding the 
subject’s hematocrit threshold (Steurer et al., 1996). 
Basile et al. (2001) conducted a prospective randomized crossover study utilizing 
bicarbonate dialysis treatment in addition to BVM-guided UF. Their study revealed that BVM 
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improved intra- and inter- dialytic symptoms, specifically symptomatic IDH related to 
hypovolemia (p < 0.02). Basile et al. (2001), also analyzed the effectiveness and safety of long-
term dialysate monitoring. Although Basile et al. (2001), did not measure the sodium mass 
balance directly, there was sufficient evidence to suggest that that sodium balance was not 
different between the gold standard bicarbonate treatment and the bicarbonate treatment with 
BVM. Blood pressure, body weight, and serum sodium levels remained unchanged and were 
identical in a follow up of two years (Basile et al., 2001).  
Santoro et al. (2002) utilized a multicenter prospective randomized crossover study to 
demonstrate that the decrease in IME was due to BVM allowance for greater equilibrium 
throughout the dialysis treatment. This subjected the body to fewer extreme conditions, both in 
refilling and pressure. The decreased exposure to extreme conditions led to saved energy and 
contributed to a decrease in morbid symptoms (Santoro et al., 2002). Sessions complicated by 
IDH was 33.5% in group A (alternating between standard HD followed by BVM treatment) and 
23.5% in the group B (BVM treatments were initiated first followed by SHD) (p = 0.004) 
(Santoro et al., 2002). Group A IDH rates decreased from 34% to 20% when transitioning from 
SHD to BVM HD (Santoro et al., 2002).  In group B, IDH rates went from 31% in the BVM 
period to 30% in the SHD period (p > 0.05). In the second trial, the IDH rates increased from 
28% in the BVM period to 39% in the conventional HD period (Santoro et al., 2002). Rates of 
interdialytic symptoms were also significantly reduced (p < 0.001), and better post dialysis 
tolerance was noted (p < 0.001) (Santoro et al., 2002). The patient population that received the 
greatest benefit from the application of BVM were unstable cardiovascular patients – the more 
critical the patient, the greater the benefits (Santoro et al., 2002).  Patients with refilling problems 
and those who have significant intradialytic hypovolemia reaped more benefits from the 
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continuous use of BVM as compared to patients with good plasma refilling rates, but with 
cardiomyopathies (Santoro et al., 2002). 
In a randomized crossover study, Gabrielli et al. (2009), observed that treatments 
utilizing BVM had a reduction of IME from 40% to 32% compared to SHD (p = 0.02). BVM 
was effective in 46% of the sample (Gabrielli et al., 2009). The rate of symptomatic IDH and the 
average number of episodes were dramatically reduced with the use of BVM (p = 0.04) 
(Gabrielli et al., 2009). The need for intervention for IMEs and IDH were reduced, but did not 
reach statistical significance (p > 0.05) (Gabrielli et al., 2009). The blood pressures and heart 
rates from the beginning to the end of HD treatments were not significantly different between the 
BVM group and the control group (p > 0.05) (Gabrielli et al., 2009).    
Gil et al. (2014) conducted a prospective crossover study and found that IDH was 
significantly reduced with the use of BVM (p < 0.001). Other observed benefits were a 
significant reduction in time to recover from fatigue after dialysis (p = 0.048) and a greater 
reduction in IDH related nursing interventions (p < 0.001) (Gil et al., 2014). The lower the rate 
of IDH, the less the degree of patient fatigue after dialysis (p = 0.002) (Gil et al., 2014). These 
results were seen among diabetic and non-diabetic patients (Gil et al., 2014). The number of 
IMEs without IDH did not significantly differ between SHD and BVM sessions (p > 0.05) (Gil et 
al., 2014). 
Saxena et al. (2015) conducted a longitudinal pilot study and evaluated the use of BVM 
with BTM compared to a control group not receiving BVM with BTM in a patient population 
noncompliant with fluid restrictions. The researchers found dialysis treatments uneventful – no 
incidence of IDH or IMEs. The patients remained stable throughout the dialysis treatment 
(Saxena et al., 2015). The authors demonstrated that the use of BVM and BTM was highly 
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accurate and delivered safe HD to a patient population with increased interdialytic weight gain 
and noncompliance (p = 0.012) (Saxena et al., 2015). Study findings also included that patient 
BP during treatments was >120/80 mmHg and that no IDH symptoms occurred, as patients were 
overhydrated and did not achieve target weight (Saxena et al., 2015).  
A systematic review and meta-analysis by Nesrallah et al. (2013) revealed that patients 
who received the BVM treatments had lower IDH rates, along with a reduction of IDH-
associated symptoms. Out of the eight studies included in the meta-analysis, six of the studies 
changed the sodium concentration of the dialysate and the UF rate to maximize plasma refilling 
(Nesrallah et al., 2013). Sodium biofeedback can theoretically cause positive sodium balance in 
HD patients, however, the decreased rate of IDH in the study was not associated with increased 
pre-dialysis BP, target weight (estimated patient weight, the goal weight trying to obtain after 
HD treatment), interdialytic weight gain, or post-dialysis sodium serum levels (Nesrallah et al., 
2013). The data did not suggest that lower rate of IDH with the use of sodium modeling resulted 
in positive sodium loading (Nesrallah et al., 2013). 
In Nesrallah et al’s (2008) randomized control study, the authors primarily studied BVM 
and its effects in extracellular fluid volume (ECFV). The authors reported that the frequency of 
IDH was decreased with the use of BVM compared to SHD treatments (p = 0.04). Since the 
BVM device also influences dialysate conductivity, it could potentially affect the patient’s serum 
sodium base balance. However, serum sodium level changes were negligible and were not 
statistically significant (p > 0.05) (Nesrallah et al., 2008).  
Sentveld et al. (2008) conducted a prospective crossover study to determine whether 
BVM was beneficial in improving hemodynamic stability and quality of life in HD patients as 
compared to SHD. The study findings demonstrated that the use of BVM resulted in a 
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significantly decreased pre-dialysis SBP (p = 0.003). Increased post-dialysis SBP was noted in 
both groups, the SHD phase to the BVM phase (p = 0.018), and in the BVM phase to SHD phase 
(p = 0.043) (Sentveld et al., 2008). Treatment time remained unchanged; thus, the duration of 
treatment was not responsible for increased hemodynamic stability (Sentveld et al., 2008). 
Quality of life in relation to post-dialysis fatigue was not significantly different between the 
control and the intervention group (p > 0.05); however, there was a significant difference in 
fatigue when switching from the BVM to the SHD phase (p = 0.035) (Sentveld et al., 2008). 
Franssen at al. (2005) utilized a prospective clinical trial to study whether BVM 
improved post-dialysis BP levels in IDH-prone patients and whether BVM is effective in 
decreasing post-dialysis weight. IDH requiring intervention dropped from 64% (SHD phase) to 
37% (BVM phase with constant target weight), and 28% (BVM phase with target weight 
reduction) (p < 0.01). Post-dialysis SBP with BVM (constant weight and with target weight 
reduction) was higher compared to those with SHD, but it was not statistically significant (p = 
0.07), p = 0.15 respectfully) (Franssen et al., 2005). Alternatively, post-dialysis diastolic BP with 
BVM was significantly higher compared to SHD (p < 0.05) (Franssen et al., 2005). Monitoring 
BP post dialysis revealed an increase in SBP during the first 16 hours after the end of treatment 
in the BVM group as compared to the control group (p < 0.05) (Franssen et al., 2005).  These 
findings can be attributed to: 1) BVM prevented extreme fluctuations of RBV and led to 
improved hemodynamic stability and 2) stress caused by IDH required a recovery time (Franssen 
et al., 2005). During the recovery time, the autonomic nervous system is less responsive to low 
blood pressure by increasing heart rate and/or vasoconstriction and thus inhibits BP variation 
(Franssen et al., 2005).   
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Du Cheyron et al. (2010) studied BVM in an acute kidney injury (AKI) patient 
population in the intensive care unit (ICU) in a prospective randomized control trial. The authors 
found that the implementation of BVM with blood temperature controls are feasible and safe (Du 
Cheyron et al., 2010). The rate of hypotension decreased from 29% to 17% with the use of BVM 
and blood temperature controls (p = 0.03) (Du Cheyron et al., 2010). 
Some studies demonstrated no significant differences in IDH and IMEs. Four of the 17 
studies found no correlation between BVM and decreased rates of IDH and IMEs.    
In a prospective clinical crossover trial, Sentveld et al. (2008) that the frequency of 
complaints associated with hypotension was reduced in both the BVM and the SHD group, but 
the frequency did not reach statistical significance (p > 0.05). The participants had a SHD, 
followed by BVM phase, and then another SHD phase. For the BVM group, the incidence of 
complaints was 8.8% while the SHD groups in phase one and three were 14.6% and 12.8% 
(respectively), but the results were not statistically significant (p > 0.05) (Sentveld et al., 2008). 
Leung et al. (2017) conducted a randomized single-blind crossover trial assessing 
whether BVM alone or BVM with adjustments to the dialysate resulted in a decrease in the 
frequency of symptomatic IDH compared to SHD (control group). Leung et al. (2017) noted that 
when the intervention treatment period data were combined, the rate of IDH did not differ 
between the BVM intervention group and the control group (p = 0.29). The rate of IDH was 
lower in the control period than in the run-in period (the period of the trial in which the dialysis 
prescription was standardized, and target weights were adjusted), showing a 50.8% decline (p = 
0.01). There were no significant differences in the degree of change in the frequency of IDH 
from the run-in period to the control or the run-in period to the BVM period (p = 0.55) (Leung et 
al., 2017). The number of treatments with symptomatic IDH (p = 0.52), asymptomatic IDH (p = 
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0.67), and IMEs (p = 0.96) were consistent in relation to the primary analysis (Leung et al., 
2017). The rate of asymptomatic IDH, symptomatic IDH or IMEs was not decreased with the use 
of BVM (Leung et al., 2017). 
Du Cheyron et al. (2013) conducted a prospective three-arm randomized controlled trial 
and compared the risks and benefits between BVM alone, BVM with BTM biofeedback, and 
SHD with cool dialysate and high sodium conductivity. Du Cheyron et al. (2013) determined that 
there was no difference in the rate of IDH between the BVM intervention group and the control 
group in an AKI ICU patient population (p = 0.99) (Du Cheyron et al., 2013). SHD was also 
compared with BVM and blood temperature monitoring and there was no decrease in the rate of 
IDH (p = 0.39) (Du Cheyron et al., 2013). 
Booth et al (2011) conducted a prospective audit of BVM records of 72 stable outpatient 
adults to determine the usefulness of BVM. No relationship between BP and BVM could be 
determined (Booth et al., 2011). A drop in SBP of ≥20mm Hg did not show a correlation with 
the use of BVM or with the amount of fluid removed (Booth et al., 2011).  
Adequacy & Target Weight  
Adequacy in dialysis is measured by Kt/V values. These values can be determined by two 
methods. One method is inserting the average blood volume processed during a dialysis 
treatment into the interface of the dialysis machine, the value is determined by an algorithm in 
the dialysis machine system and this is an estimated Kt/V value or single pool Kt/V (Advanced 
Renal Education Program, 2015). This algorithm suggests that urea is confined to one 
compartment in the body (Advanced Renal Education Program, 2015). The second, more precise 
measurement of adequacy, called double pool or equilibrated Kt/V, is drawing a serum sample 
(Advanced Renal Education Program, 2015). The result of the serum sample is plugged into the 
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algorithm to determine the adequacy for the month (Advanced Renal Education Program, 2015). 
Both are utilized in clinical practice, however, the double pool Kt/V is used to determine HD 
prescription change.   
Target weight is the goal weight to be achieved at the end of HD treatment. It helps 
determine the amount of fluid to be removed and it is the anticipated post weight of the patient. It 
has been suggested that BVM can increase adequacy and better determine precise target weights 
(KDOQI, 2005).  
Out of the 17 studies, 10 addressed target weight and/or adequacy (target weight [2], 
adequacy [4], both target weight and adequacy [4]). Two of the six studies found no relation to 
and/or not significant differences between target weight and BVM (Franssen et al., 2005; Gil et 
al., 2014; McIntyre et al., 2003; Nesrallah et al., 2008). Four out of the eight studies found no 
significant correlation between adequacy and BVM (Franssen et al., 2005; Gil et al., 2014; 
Nesrallah et al., 2008; Santoro et al., 2002).   
McIntyre et al. (2003) conducted a prospective study and demonstrated that although the 
use of BVM did not affect target weight, there was a significant decrease in interdialytic weight 
gain in unstable patients (p = 0.009). The researchers hypothesized that the decreased 
interdialytic weight gain was due to a reduced thirst which occurred immediately after treatment. 
McIntyre et al. (2003) also reported a significant increase in urea clearance with BVM as 
compared to SHD (single pool p = 0.03, equilibrated p < 0.01).  
In a randomized control study, Nesrallah et al. (2008) determined that extracellular fluid 
volume and target weight were not reduced during the six month timeframe of the study. There 
was no relationship between BVM and Kt/V (Nesrallah et al., 2008). 
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Santoro et al. (2002) conducted a prospective randomized crossover trial and determined 
that the Kt/V delivered during treatment was not significantly different, the control group and the 
BVM group (p > 0.05). Weight loss between both groups was not significantly different (p > 
0.05) (Santoro et al., 2002). The high responders (those benefiting the most from BVM) achieved 
a weight 0.5 kg higher than those in SHD at the same weight loss (Santoro et al., 2002). The poor 
responders (those not benefitting from BVM) had a lower post-dialysis weight with BVM than 
with SHD (0.2 kg), but this corresponded with a higher total weight loss than SHD period (2.9 kg 
[SHD] vs. 3.3 kg [BVM]) (Santoro et al., 2002) 
In critical AKI patients, the incidence of hypotension was inversely related to adequacy 
(Du Cheyron et al., 2010). Findings from this prospective randomized control study reported a 
decrease in IDH, with the delivered Kt/V of 1.36 (± 0.39), exceeding the goal of 1.2 (Du 
Cheyron et al., 2010).  
In a different prospective three-arm randomized control trial by Du Cheyron et al. (2013), 
the observed median Kt/V of 1.2 exceeded the prescribed goal. 
In a pilot study by Saxena et al. (2015), the researchers reported that the BVM group was 
better able to tolerate UF during treatments than the SHD group (3L of fluid removal in the 
BVM group versus 1.9L in the SHD group).  
Winkler et al. (2008) used a descriptive clinical study to evaluate a possible reduction in 
lower target weights after BVM sessions in combination with lower dosage antihypertensive 
drug therapy. BVM use decreased fluid overload of pure water caused by diabetes and 
intermittent hyperglycemia (Winkler et al., 2008). Other benefits of BVM included higher Kt/V 
results (p < 0.05, single pool; p < 0.05, double pool) as compared to SHD.   
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In a crossover study, Sentveld et al. (2008) concluded that larger UF rates could be 
achieved with BVM as compared to SHD (p = 0.049). The researchers also demonstrated a 
significant decrease in target weight with the use of BVM as compared to SHD (p = 0.032) 
(Sentveld et al., 2008).  
Gil et al. (2014) completed a prospective crossover study which demonstrated that the 
body weight (pre-dialysis weight [p = 0.456], post-dialysis [p = 0.432]) and intradialytic weight 
gain (p = 0.320) did not differ from the BVM group and the control group (SHD group). Dialysis 
adequacy measured by urea did not differ between the BVM group and the SHD control group (p 
= 0.910) (Gil et al., 2014). 
 Franssen et al. (2005) completed a prospective study and noted that the Kt/V and target 
weight reductions did not differ between the control (SHD) and the BVM group. Failure to 
reduce target weight with BVM necessitated modification of target weight by changing the 
dialysis prescription (e.g., increasing treatment time) (Franssen et al., 2005).   
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DISCUSSION 
Synthesis of current literature demonstrated the effectiveness of BVM in decreasing the 
incidence of IDH (Basile et al., 2001; DuCheyron et al., 2010; Franssen et al., 2005; Gabrielli et 
al., 2009; Gil et al., 2014; McIntyre et al., 2003; Nesrallah et al., 2013; Nesrallah et al., 2008; 
Santoro et al., 2002; Saxena et al., 2015; Sentveld et al., 2008; Steuer et al., 1996; Veljančic et 
al., 2011). BVM alleviated intradialytic symptoms of IDH such as muscle cramps, nausea, 
dizziness, headache vomiting, unconsciousness, or other adverse symptoms requiring nursing 
intervention (Basile et al., 2001; Gabrielli et al., 2009; McIntyre et al., 2003; Santoro et al., 2002; 
Saxena et al., 2015; Steuer et al., 1996; Veljančic et al., 2011; Winkler et al., 2008). The benefits 
of BVM use were seen in both patients prone to IDH and in non-IDH prone patients (Basile et 
al., 2001; DuCheyron et al., 2010; Franssen et al., 2005; Gabrielli et al., 2009; Gil et al., 2014; 
McIntyre et al., 2003; Nesrallah et al., 2013; Nesrallah et al., 2008; Santoro et al., 2002; Saxena 
et al., 2015; Sentveld et al., 2008; Steuer et al., 1996; Veljančic et al., 2011). Patients in a more 
critical condition, such as unstable cardiovascular patients, experienced greater benefit from the 
use of BVM (Santoro et al., 2002).  
BVM allows greater blood volume stability, which fosters less extreme conditions in 
refilling and pressure rates (Santoro et al., 2002). Improved refilling rates increased ejection 
fraction and nearly normalized LV mass index (Winkler et al., 2008). Patients who experienced 
IDH and IDH-related symptoms did so at specific hematocrit thresholds (Steurer et al., 1996). 
This threshold was consistent with successive treatments (Steurer et al., 1996).  
The studies using sodium modeling in conjunction with BVM did not lead to positive 
sodium loading after dialysis treatments (Basile et al., 2001; Nesrallah et al., 2013; Nessrallah et 
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al., 2008). Blood pressure, body weight, and serum sodium levels remained the same in the 
subsequent two years (Basile et al., 2001; Nesrallah et al., 2013; Nessrallah et al., 2008).   
The literature synthesis showed no consensus on the improvement in the dialysis 
adequacy and optimal target weight. Several studies measured Kt/V by a single pool and 
equilibrated pool, however not all studies measured both or differentiated the values between the 
two.   
Although BVM technology was determined to be effective and allows for a safer dialysis 
treatment, nursing judgment continues to be essential to provide high-quality and safe care to 
patients. This includes advocating for an increase or decrease in hematocrit thresholds, so the 
patient continues to reap benefits with the utilization of BVM during routine HD treatments.  
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LIMITATIONS 
Although the majority of the research studies analyzed in the literature review were 
randomized controlled trials, studies higher in the hierarchy of evidence, there are limitations to 
the literature review findings. One limitation is that not all the included studies used BVM as the 
only independent variable. Some studies included BTM or sodium biofeedback with BVM (Du 
Cheyron et al., 2013; Du Cheyron et al., 2010; Nesrallah, 2013; Nesrallah et al., 2008; Saxena et 
al., 2015; Steurer et al., 1996; Veljančic et al., 2011; Winkler et al., 2008;). It was unclear 
whether the benefits of reduced IDH and IMEs were attributed solely to the BVM.  
Another limitation was that each study defined IDH differently. Some studies used the 
KDOQI guidelines (Basile et al., 2001; Booth et al., 2011; Leung et al., 2017; Saxena et al., 
2015), and others described a hypotensive episode as one that required nursing intervention or 
one that resulted in IMEs (DuCheyron et al., 2013; Gabrielli et al., 2009; Veljančic et al., 2011). 
Other definitions included a drop in BP of ≥20 mmHg with symptoms (Frannsen et al., 2005; Gil 
et al., 2014; Sentveld et al., 2008) or without symptoms (McIntyre et al., 2003). Other studies 
created their own definition of hypotension such as DuCheyron et al. (2010), who described IDH 
as SBP < 90 mm Hg or a drop in SBP of > 40 mm Hg from baseline that required intervention. 
Santoro et al. (2002) defined IDH as: 1. a reduction of SBP to < 90 mm Hg with application of 
nursing interventions, or 2. a combination of pre-dialysis SBP of ≥100 mm Hg with a decrease in 
SBP ≤ 90 mmHg without symptoms, predialysis SBP of <100 mm Hg with symptoms or a 
reduction in SBP of ≥25 mm Hg with symptoms. Nesrallah et al. (2008) defined IDH more 
conservatively as a reduction in SBP of >10 mm Hg, requiring nursing intervention. Steuer et al. 
(1996) used IMEs as end points into his study and included IMEs as an event, regardless of a 
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drop in BP. Winkler et al. (2008) did not define IDH but did include IMEs, such as muscle 
cramping.  
Another limitation is the lack of studies within the last five years that address BVM 
technology and its effects on IDH. Five studies are research published within the last 5 years, 
indicating a gap in current literature. Additional research is warranted to determine the efficacy 
of BVM to prevent IDH and other clinically relevant benefits of BVM.  
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CONCLUSION 
The literature review demonstrated that BVM is effective in preventing IDH and IME 
events. Results did not reveal a strong correlation between BVM and decreased target weights or 
increased dialysis adequacy (Kt/V). A clear global definition of IDH is needed based on the 
widely disparate definitions used in the studies. Further research is merited that can examine the 
effects of BVM use alone without the addition of other variables. The lack of recent studies in 
the literature indicates that more research is merited in the use of BVM technology with dialysis 
patients to support the use of BVM in clinical settings and to determine the population that will  
benefit the most from this intervention. The barriers which prevent the implementation of BVM 
in clinical settings warrants consideration.   
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TABLE 2: SUMMARY TABLE OF RESEARCH LITERATURE ON BLOOD VOLUME MONITORING  
     
Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Randomize
d crossover 
trial of 
blood 
volume 
monitoring-
guided 
ultrafiltratio
n 
biofeedback 
to reduce 
intradialytic 
hypotensive 
episodes 
with 
hemodialysi
s. 
Leung 
K.C.W., 
Quinn 
R.R., 
Ravani P., 
Duff H., 
and 
MacRae 
J.M. 
(2017) 
Randomiz
ed single 
blind 
Crossover 
Trial 
n= 32 
Mean age 67, women in 
sample 17%, years in 
dialysis 3.65, BMI 30, race: 
White 17%, Asian 10%, 
Other 6%; cause of ESRD: 
DM, HTN, GN, obstructive 
and other. Access: AVF 
12% and CVC 20%.     
Inclusion criteria:  Age >18, 
medically stable, on HD for 
>3 months, treating 3-4 
x/week for at least 3 hours 
and ≥30% HD treatments 
complicated by 
symptomatic IDH in the 
preceding 8 weeks. 
Exclusion criteria: serum 
hemoglobin <8.0 g/dl, 
serum sodium <133 meq/L 
active malignancy, history 
of blood transfusion or 
hospitalization in the 
preceding 4 weeks, ongoing 
urine output estimated 
≥250mL/day, routinely 
used diuretics for volume 
management, a planned 
change in the renal 
replacement modality 
Evaluate 
whether 
BVM alone 
without 
adjustment of 
dialysate 
resulted in 
decrease in 
symptomatic 
IDH when 
compared to 
best clinical 
practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BVM did 
not reduce 
the rates of 
symptomati
c IDH, 
asymptomat
ic IDH or 
symptoms 
alone (p= 
0.29). 
More 
studies to 
determine 
the specific 
population 
and the 
optimal 
critical 
blood 
volume to 
best utilize 
this 
technology.  
S: 
manipulative 
variable is 
BVM, 
washout 
period, 
target weight 
assessed 
weekly, 
defined IDH 
and 
predisposed 
IDH sample. 
L: Small 
sample size, 
strict 
inclusions 
and 
exclusion 
criteria 
(<10% of 
those 
screened 
were in the 
study), and 
not every BP 
reading was 
analyzed.     
Manipulati
ve variable 
is BVM.  
Level I 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
during the study period, or 
unable to provide written 
informed consent. 
Setting: Five outpatient HD 
centers in Calgary, Alberta, 
Canada.  
Non-
invasive 
method for 
preventing 
intradialytic 
hypotension
Saxena A., 
Sharma 
R.K., 
Gupta A., 
and John 
M.M. 
(2015) 
Longitudi
nal Pilot 
Study 
n= 40 
Mean age 41.5 yrs, height 
(cm) 165.5, BMI 21.1, 
Hemoglobin (Hbg) (mg%) 
8.44, Hematocrit (hct) (%) 
27.8, platelets 196,000, 
serum albumin (g/dL) 3.4, 
Evaluate the 
feasibility of 
BVM and 
blood 
temperature 
monitoring 
(BTM) 
BVM with 
BTM 
strongly 
correlated 
with a 
reduced rate 
of IDH, the 
BVM with 
BTM 
should be 
included in 
the dialysis 
protocol.  
S: IDH 
defined 
according to 
KDOQI 
guidelines 
and no 
consumption 
Interventio
n included 
BVM.  
Level 
IV 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
: a pilot 
study. 
and serum creatinine mg 
(%) 8.2   
Inclusion criteria: ≥ 18-
years of age, non-diabetic, 
dose of erythropoietin 
constant for ≥3 months.  
Exclusion criteria: overt 
CHF, cardiac arrhythmia, 
severe carotid stenosis, 
history of symptomatic 
cerebral vascular disease, 
and positive viral markers 
(HBV and HIV).  
Setting: Dialysis unit in 
tertiary care hospital 
(India).  
preventing 
IDH prone 
patients due 
to 
noncomplian
ce to fluid 
restrictions 
and to assess 
changes in 
water 
compartment
s.  
use of 
nursing 
intervention
s, and intra- 
and inter- 
dialytic 
symptoms 
(p=0.012). 
 
of food or 
fluids 
allowed to 
prevent 
food-
induced 
IDH. 
L: Unclear 
which 
intervention 
influenced 
results, no 
female in 
sample, and 
patients 
received HD 
2X/week.  
Efficacy of 
hemocontro
l 
biofeedback 
system in 
intradialytic 
hypotension
-prone 
hemodialysi
s patients. 
Gil H.W., 
Bang K., 
Lee S.Y., 
Han B.G., 
Kim J.K., 
Kim Y.O., 
Song H.C., 
Kwon Y.J., 
and Kim 
Y.S. 
(2014) 
Multi-
center 
prospectiv
e 
crossover 
study 
n= 60 
Age 57, Male 31.6%, 
Diabetes 31.6%, HTN 
63.3%, mean time in 
dialysis 58.3, vascular 
access: AVF 76.7% and 
AVG 23.3%, hgb (g/dL) 
10.6, serum albumin (g/dL) 
3.84, and Antihypertensive 
meds ACE or ARBs 50%, 
CCB 43.3%, α or β blocker 
41.7%, Direct vasodilator 
3.3%.       
Inclusion criteria: chronic 
HD patients on 3x/week 
HD, >3 months on HD, 
Determine 
whether 
hemocontrol 
biofeedback 
system 
(HBS) 
improves 
IDH in IDH 
prone 
patients 
compared 
with 
conventional 
HD.  
HBS 
reduces 
occurrence 
of IDH (p 
<0.001), 
promote 
faster 
recovery 
from post 
dialysis 
fatigue 
(p =0.048), 
and 
decreases 
IDH related 
nursing 
HBS in 
clinical 
setting to 
reduce IDH.   
S: First 
multicenter 
prospective 
study that 
assessed 
HBS in 
Asian patient 
population, 
large sample 
size, defined 
IDH similar 
to KDOQI 
guidelines, 
and used 
multiple 
centers.  
HBS is a 
form of 
BVM. 
Level II 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
>25% incidence of IDH 
during the last month 
preceding the study, age 18-
74, ability to provide 
consent, and interdialytic 
weight gain >1.5 kg.  
Exclusion criteria: pre-
dialysis MAP in supine 
position < 90 mmHg, 
delivered blood flow rate 
for dialysis < 200 mL/min, 
pre-dialysis hemoglobin 
level > 13 g/dL, treatment 
by hemodiafiltration, 
unstable angina, myocardial 
infarction, decompensated 
congestive heart failure, 
history of hemodynamically 
important valvular heart 
disease, and expected need 
for blood transfusions.  
Setting: 9 outpatient HD 
centers (Korea).  
 
intervention
s (p 
<0.001). 
L: Results of 
the study 
cannot be 
generalized 
to other 
populations, 
cardiovascul
ar disease 
was 
determined 
by history, 
crossover 
design bias 
on subjective 
assessment, 
and target 
weight 
assessed by 
study 
physician 
based on 
clinical 
evaluation.   
  
37 
 
     
Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Biofeedbac
k dialysis 
for 
hypotension 
and 
hypervolem
ia: a 
systematic 
review and 
meta-
analysis. 
Nesrallah 
G.E., Suri 
R.S., 
Guyatt G., 
Mustafa 
R.A., 
Walter 
S.D., 
Lindsay 
R.M., and 
Akl E.A. 
(2013) 
Systematic 
Review & 
metanalysi
s  
Inclusion criteria: age >18, 
3x/week dialysis for at least 
90 days, chronic fluid 
overload and symptomatic 
IDH.  
Exclusion criteria: Varied 
by study included reduced 
life expectancy, severe 
anemia, pregnancy, and 
cardiac arrhythmia. 
Setting: ICHD. 
To determine 
whether 
biofeedback 
HD using 
biofeedback 
UF and/or 
variation in 
dialysate 
conductivity 
improves 
outcomes in 
patients with 
chronic fluid 
overload or 
symptomatic 
IDH 
compared 
with constant 
UF and 
conductivity.  
 
Biofeedbac
k dialysis 
statistically 
and 
clinically 
significant 
reduced 
frequency 
of   IDH. 
No 
evidence of 
harmful 
effects such 
as sodium 
loading 
with 
variation of 
dialysate 
conductivit
y.   
Biofeedbac
k 
technology 
should be 
considered 
for IDH 
prone 
patients and 
those with 
expanded 
ECF 
volume.   
S: Imposed 
no language 
restriction on 
language of 
publication, 
used detailed 
search 
strategy, 
limited 
metanalysis 
to patient 
important 
outcomes.  
L: Studies 
were single 
blinded, 
unclear of 
randomizatio
n techniques, 
studies 
included 
biofeedback 
that adjusted 
dialysate 
conductivity 
unclear 
which 
intervention 
was 
effective.   
BVM 
biofeedbac
k was the 
interventio
n 
implement
ed to guide 
UF and 
conductivit
y dialysate.  
Level I 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Use of 
online 
blood 
volume and 
blood 
temperature 
monitoring 
during 
haemodialy
sis in 
critically ill 
patients 
with acute 
kidney 
injury: a 
single-
centre 
randomized 
controlled 
trial. 
du 
Cheyron 
D., Terzi 
N., Seguin 
A., Valette 
X., Prevost 
F., 
Ramakers 
M., 
Daubin C., 
Charbonne
au P., and 
Parienti 
J.J. (2013) 
Prospectiv
e single 
center 
three arm 
randomize
d 
controlled 
trial 
n= 74 
Average Age 65, , male 
gender 68%, BMI 26.7, 
comorbidities: HTN 47%, 
CAD 27%, DM 100%; 
Cause of AKI: septic shock 
43%,  cardiogenic 26%, 
hypovolemia 11%, drug 
induced 8%, and other 
12%; BUN 18.2 mmol/L, 
serum creatinine 245 
μmol/L, number of sessions 
4.5, number of days on 
RRT in ICU days 9, length 
of ICU stay 15 days, and 
mortality 42%.  
Inclusion criteria: AKI, ≥18 
years with the first line of 
RRT as intermittent 
hemodialysis. 
Exclusion criteria: ESRD, 
patient requiring renal 
replacement therapy that 
was first initiated with 
continuous veno-venous 
hemofiltration, and AKI 
dialysis session performed 
with an a priori intentions 
for no UF.  
Setting: Medical ICU 
admission (France). 
Compare the 
risks and 
benefits of 
HD protocols 
either with 
BV 
biofeedback 
or both BV 
and BT 
biofeedback 
compared to 
standard 
dialysis 
therapy with 
cool dialysate 
and high 
sodium 
conductivity.  
No 
significant 
difference 
in 
occurrence 
of IDH with 
BVM and 
BVM with 
BTM 
compared 
to standard 
dialysis 
treatment (p 
= 0.99). 
Further 
research is 
warranted 
before 
BVM 
technology 
is routinely 
used in ICU 
setting.  
S: Included 
all AKI 
related 
dialysis 
session with 
UF and 
study design.   
L: Small 
sample size, 
critically ill 
patients are 
more prone 
to IDH 
versus stable 
ESRD 
patient, 
decreased 
population 
variety, lack 
of blinding 
to medical 
team, and 
inability to 
determine 
critical BV. 
BVM was 
tested 
alone as an 
interventio
n and 
compared 
to BVM 
with BTM  
Level I 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Do changes 
in relative 
blood 
volume 
monitoring 
correlate to 
hemodialysi
s-associated 
hypotension
? 
Booth J., 
Pinney J., 
and  
Davenport 
A. (2011) 
Prospectiv
e Audit  
n=72 
36.1% diabetic patients 
with 20.8% with prescribed 
insulin, mean age 55 years, 
males and females 
(50%/50%).  
Exclusion criteria: Patients 
with implanted 
defibrillators and 
resynchronization 
pacemakers, patients unable 
to stand on the 
bioimpedance machine. 
Setting: University dialysis 
center (UK).  
Assess the 
usefulness in 
relative BVM 
audited 
changes in 
relative blood 
volume in 
heathy CKD 
HD 
outpatients to 
determine 
whether there 
was a 
correlation 
with IDH. 
Unable to 
determine 
any 
relationship 
between 
changes in 
BVM and 
intradialytic 
blood 
pressures.  
 
BVM 
techniques 
solely based 
on 
hematocrit 
could 
potentially 
underestima
te the effect 
of UF on 
plasma 
volume.  
S: Patients 
refrained 
from eating 
during HD 
but could 
drink 180mL 
of fluid. 
Large 
sample size.  
L: 
Population 
study did not 
include IDH 
prone 
patients, 
audit study 
design, no 
inclusion 
criteria, and 
did not 
define IDH. 
BVM was 
the 
manipulati
ve 
variable.  
Level 
III 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Simultaneo
us blood 
temperature 
control and 
blood 
volume 
control 
reduces 
intradialytic 
symptoms. 
Veljančic 
L., 
Popović J., 
Radović 
M., 
Ahrenholz 
P., 
Ries W., 
Frenken 
L., and  
Wojke R. 
(2011) 
Randomiz
ed 
crossover 
clinical 
trial 
n= 26 
Mean age 56.1 years, mean 
time in dialysis 6.3 years, 
12 males and 14 females, 
comorbidities (n): HTN 
(12), CAD (6), LVH (6), 
and DM (2).   
Inclusion criteria: Three 
European countries study 
population, ≥18 years, 
thrice weekly HD 
treatments lasting at least 3 
hours, and a history of 
cardiac instability during 
HD. Exclusion criteria: 
Severe instabilities with 
blood pressure medications, 
severe anemia, vascular 
access problems, single 
needle treatment, HD with 
varying dialysate sodium 
concentration or varying 
ultrafiltration rates.  
Setting: 6 European dialysis 
centers.  
To 
investigate 
the clinical 
benefit of 
simultaneous 
control of 
BTM and 
BVM.  
Combined 
use of 
BVM and 
BTM 
provided an 
average of 
45% fewer 
intradialytic 
complicatio
ns 
compared 
to standard 
HD 
(p =  
0.024). 
In a 
population 
with high 
incidence of 
IME 
combined 
application 
of both 
individualiz
ed 
automatic 
biofeedback 
systems is 
suggested 
as a 
preventative 
measure.  
S: Sample 
prone to 
IMEs, 
screening 
phase in 
which 
individual 
patient 
critical BV 
was 
determined, 
and defined 
IME.  
L: Inability 
to 
distinguish 
the 
intervention 
that caused 
the 
significant 
improvemen
ts in IMEs, 
the 
intervention 
was not 
blinded by 
no blinding, 
and small 
sample size. 
BVM was 
used as an 
interventio
n 
alongside 
BTM.  
Level I 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Blood 
volume- 
and blood 
temperature
-controlled 
hemodialysi
s in 
critically ill 
patients: a 
6-month, 
case-
matched, 
open-label 
study. 
du 
Cheyron 
D., 
Lucidarme 
O., Terzi 
T., and 
Charbonne
au P. 
(2010) 
Prospectiv
e open 
label, case 
matched 
study  
n=20 
Historical Control: n=42. 
Age 61, male 43%, 
comorbidities: hypertension 
38% and cardiomyopathy 
10%. Origin medicine 86%.  
Cases: Age 59, male 60%, 
Comorbidities: 
hypertension 60% and 
cardiomyopathy 30%. 
Origin medicine 85%. 
Age 61, male 43%,   
Inclusion criteria: AKI in 
oliguric stage dialyzed 
exclusively by intermittent 
hemodialysis (IHD).  
Exclusion criteria: Patients 
with end-stage renal disease 
and dialysis treatments 
involving administration of 
packed red blood cells. 
Setting: Medical ICU 
(France).   
Test the 
feasibility 
and safety of 
concurrent 
BV and BT 
monitoring 
during HD.   
Blood 
volume 
monitoring 
and blood 
temperature 
monitoring 
proved to 
decrease 
incidence of 
hypotension 
and 
maintain 
hemodyna
mic 
stability (p 
= 0.03).  
Simultaneo
us BV and 
BT 
monitoring 
are safe and 
feasible in 
AKI patient 
in the ICU.  
S: Defined 
safe, 
feasibility, 
and 
hypotension. 
Each pair of 
patients and 
dialysis 
treatment 
had to fulfill 
4 conditions: 
case patients 
should have 
the same age 
( ±5 years) 
and the same 
SAPS II 
(±10 points) 
at ICU 
admission as 
historical 
controls; and 
among these 
pairs of 
patients, 
online 
monitoring 
dialysis 
sessions 
should have 
the same 
dialysate 
sodium 
Manipulati
ve variable 
is BVM 
technology
.  
Level II 
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Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
concentratio
n ( ±1  
mmol/l) and 
the same net, 
ultrafiltratio
n per session 
( ±500mL) 
as 
conventional 
dialysis 
sessions, and 
no 
statistically 
significant 
differences 
between the 
groups.  
L: AKI 
oliguric 
patients were 
the focus of 
the study. 
The 
treatment 
modality 
included 
temperature 
and blood 
volume 
monitoring, 
it remains 
unknown 
which 
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Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
variable 
caused 
increased 
hemodynami
c stability. 
ICU patients 
were the 
main 
population 
understudy. 
Small 
sample size. 
Control 
group used 
was a 
historical 
control 
group from 
2007 treated 
with 
standard 
IHD.  
 
Improved 
intradialytic 
stability 
during 
haemodialy
sis with 
blood 
volume-
controlled 
Gabrielli 
D., Krystal 
B., 
Katzarski 
K., 
Youssef 
M., 
Hachache 
T., Lopot 
F., Lasseur 
Open 
randomize
d 
crossover 
study 
n=26 
Age 69.7, mean time on 
RRT 4.5 years, % of males 
53.8, 60, sessions with IME 
47.5, Comorbidities no.: 
DM 15.4%, coronary heart 
disease 38.5%, myocardial 
insufficiency 15.4%, 
previous MI 15.4%, HF 
34.6%, peripheral 
Investigate 
differences in 
hemodynami
c stability 
when 
compared to 
standard HD 
with BVM 
controlled 
UF. 
Relative 
BVM 
biofeedback 
control of 
UF 
decreased 
the 
frequency 
of IMEs (p 
= 0.02) in 
Use of 
BVM 
without 
alteration in 
sodium 
dialysate to 
decrease 
IMEs.   
S: 
manipulative 
variable 
BVM, IME 
prone 
patients 
selected, 
eliminated 
variables 
that could 
Only 
modified 
variable 
was BVM 
guided UF.  
Level I 
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Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
ultrafiltratio
n 
C., Gunne 
T., 
Draganov 
B., Wojke 
R., and 
Gauly A. 
(2009) 
arteriopathy 34.9%, 
previous stroke 15.4%, 
HTN 69.2%, autonomous 
neuropathy 11.5%, cardiac 
arrhythmia requiring 
treatment 26.9%, and other 
30.8%; 77% were on BP 
meds and 85% were on 
EPO.  
Inclusion criteria: 3x/week 
HD with at least 180 
minutes of treatment time, 
prone to IDH, 1/3 of 
treatment was complicated 
by intradialytic morbid 
events (IME which are 
hypotension, cramps, 
nausea, vomiting, headache, 
dizziness, or other adverse 
symptoms requiring 
medical intervention).  
Exclusion criteria: 
application of blood 
temperature control, sodium 
or UF profiles, planned 
change in dialysate 
composition or dose of 
recombinant human 
erythropoietin, current 
intake of antihypotensive 
medications, frequent 
change in target weight, and 
hypotension 
prone 
patients 
from 40% 
(during 
standard 
HD) to 
32%. 
 
affect blood 
volume 
control and 
intradialytic 
stability 
were 
eliminated 
and dialysis 
and 
medication 
prescription 
were kept 
constant.      
L: patient 
and user 
bias, small 
sample size, 
and BVM 
group had on 
average 2 
minutes 
more than 
prescribed 
treatment 
time.    
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Name  
Authors 
 
Design  Sample Size, Participants, 
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Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
other severe medical 
conditions.  
Setting: Nine HD centers.  
Can 
extracellula
r fluid 
volume 
expansion 
in 
hemodialysi
s patients be 
safely 
reduced 
using the 
hemocontro
l 
biofeedback 
algorithm? 
A 
randomized 
trial 
Nesrallah 
G.E., Suri 
R.S., 
Thiessen-
Philbrook 
H., 
Heidenhei
m P., and 
Lindsay 
R.M. 
(2008) 
Open label 
randomize
d control 
study 
n = 60 
Best Clinical Practices 
(BCP) (31): Age 68, male 
67%, race: white 87%, 
black 3%, native Canadian 
10%; urine output 
>200mL/d 26%, 
Comorbidities: DM 24 
77%, HTN 84%, 
cardiovascular disease 77%; 
Medications: Diuretics 
16%, ACEI 55%, Beta 
blocker 61%, and other 
35%.    
Hemocontrol Biofeedback 
System (HBS) (29): Age 
64.1, male 55%, race: white 
86%, black 0%, native 
Canadian 14%; urine output 
>200mL/d 34%, 
Comorbidities: DM 76%, 
HTN 90%, cardiovascular 
disease 76%; Medications: 
Diuretics 28%, ACEI 48%, 
Beta blocker 59%, and 
other 45%.    
 
Inclusion criteria: HD thrice 
weekly for at least 6 months 
Examine the 
effects of 
HBS when 
compared to 
best clinical 
practices on 
ECFV and 
secondary 
outcomes in 
ECF 
expanded HD 
patients.    
HBS did 
not change 
ECFV, 
however 
did 
decrease 
frequency 
of IDH (p = 
0.04) 
compared 
to best 
clinical 
practices. 
 
It is 
possible to 
use HBS 
software to 
normalize 
hydration 
status by 
increasing 
ionic mass 
removal to 
gently 
desalt 
patients. 
Further 
studies are 
needed. 
S: Defined 
IDH, large 
sample size, 
study length, 
and baseline 
period.  
L: between 
group 
differences 
at baseline, 
selection 
criteria not 
based on 
frequent 
IDH or IME. 
Also, HBS 
used 
biofeedback 
changed 
dialysate and 
the UF rate 
according to 
RBV.     
HBS is 
BVM 
technology
, however, 
the 
biofeedbac
k system 
changed 
dialysate 
conductivit
y.  
Level I 
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Authors 
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Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
at the London Health 
Science Center, predialysis 
ECFV > 45% of total body 
water, age 18-85, blood 
flow rate ≥350mL/min, 
treatment time ≥3.5 hours, 
and hemoglobin 110-120 
g/L. 
Exclusion criteria: urine 
output >400mL/day, 
treatment with 
hemofiltration/hemodiafiltr
ation, blood transfusion 
dependence, pregnancy, 
hemodynamic instability 
due to arrhythmia, and use 
of alpha-adrenergic agents 
to prevent IDH 
Setting: London Health 
Science Center. 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
The 
influence of 
blood 
volume-
controlled 
ultrafiltratio
n on 
hemodynam
ic stability 
and quality 
of life. 
Sentveld 
B., Van 
den Brink 
M., Brulez 
H.F.H., 
Potter Van 
Loon B.J., 
Weijmer 
M.C., and 
Siegert 
C.E.H. 
(2008) 
Prospectiv
e Multiple 
crossover 
study  
n = 18 (19 enrolled 1 
moved) 
13 males and 6 females, 
mean age 64, mean time on 
HD 44 months, cause of 
RF: diabetic neuropathy 
(6), hypertensive 
nephrosclerosis (5), 
polycystic kidney disease 
(3), chronic interstitial 
nephritis (1), IgA 
nephropathy (1), Wegener’s 
granulomatosis (1), reflux 
nephropathy (1), and 
postrenal obstruction 
nephropathy (1).   
Inclusion criteria: Patients 
treated 3 times weekly with 
4-hr sessions  
Exclusion Criteria: Patients 
who received treatment for 
cardiac failure or received 
BV guided UF.  
Setting: General Dialysis 
department (Netherlands).  
Determine 
whether BV 
controlled 
UF compared 
to 
conventional 
UF is 
beneficial to 
hemodynami
c stability 
and quality of 
life.  
BVM 
demonstrate 
improved 
hemodyna
mic 
stability 
(pre-
treatment p 
= 0.003, 
post-
treatment p 
= 0.018), 
increased 
ultrafiltratio
n capacity 
(p = 0.049), 
and a 
decrease in 
dry weight 
(p = 0.032).  
But it does 
not 
demonstrate 
a change in 
quality of 
life.  
 
Use of 
BVM in 
clinical 
setting to 
increase 
hemodynam
ic stability 
and UF 
capacity in 
heterogeneo
us 
population 
of HD 
patients.   
S: 
determined 
critical BV 
before 
initiating 
intervention, 
treatment 
time 
remained 
unchanged, 
objective 
tool was 
used to 
determine 
quality of 
life, and IDH 
was defined.  
L: Small 
sample size, 
population 
did not 
equally 
represent 
females, 
sample 
population 
did not 
include IDH 
prone 
patients 
Interventio
n utilized 
was BVM 
biofeedbac
k HD.  
Level II 
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Interventio
ns 
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(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Blood 
volume 
monitoring. 
Winkler 
R.E.,  
Pätow W., 
and  
Ahrenholz 
P. (2008) 
Descriptiv
e clinical 
evaluation 
n=18 
11 males and 7 females 
mean age 56.4  
Inclusion criteria: Diabetic 
patients with known 
cardiovascular disease and 
experienced HD related 
complications like cramps 
and IDH; age ≥18, and start 
of RRT  39 months   
Exclusion criteria: none 
found.  
Setting: not described.  
 
BVM with 
regulations of 
UF and 
sodium was 
evaluated to 
describe 
advantages 
for efficacy 
and 
compatibility 
with HD.  
BVM 
improved 
the 
adequacy (p 
single pool  
<0.05, p 
double pool 
<0.05) 
compared 
to SHD and 
removal of 
pure fluid 
(p >0.05). 
Also,  
patient can 
reach 
optimal 
weight (p 
>0.05) with 
reduced HD 
related 
complicatio
ns 
(p <0.01) 
BVM offers 
a unique 
possibility 
to treat 
diabetic 
patients 
according 
to their 
special 
needs.  
S: Inclusion 
of IDH 
prone 
patients.   
L: Small 
sample size,   
BVM guided 
UF with 
sodium 
intervention 
- remains 
unknown 
which 
intervention 
proved to be 
effective, no 
sample 
description, 
and IDH not 
defined. 
Manipulati
ve variable 
in study 
was BVM 
guided UF, 
however it 
also 
included 
biofeedbac
k of 
sodium. 
Level II 
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Aim Key 
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Interventio
ns 
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(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Automatic 
feedback 
control of 
relative 
blood 
volume 
changes 
during 
hemodialysi
s improves 
blood 
pressure 
stability 
during and 
after 
dialysis. 
Franssen, 
C.F.M., 
Dasselaar 
J.J., 
Sytsma P., 
Burgerhof 
J.G.M, de 
Jong P.E., 
and 
Huisman 
R.M. 
(2005) 
Prospectiv
e study  
n=12  
Age 64.2  years, mean time 
on HD 4.5 years, causes of 
CKD: DM (5), HTN (4), 
PKD (1), lupus (1), and 
acute RF after AAA rupture 
(1), AVF and AVG (11 
total) and CVC (1), major 
cardiac comorbidity (2), BP 
meds (6)  and prescription 
unchanged throughout 
study, residual renal 
function (3), hgb 7.4 
mmol/L and albumin 37.7 
g/L.  
Inclusion criteria: chronic 
HD for >6 months, HD 3 
times/week, and 
symptomatic IDH requiring 
intervention in 50% of 
sessions over the past 6 
weeks. 
Exclusion criteria: IDH 
caused by primary cardiac 
rhythm disturbances and a 
history of frequent 
transfusions of packed red 
blood cells (defined as >2 
units/month during the past 
3 months).  
Setting: ICHD 
(Netherlands).  
Whether 
blood volume 
tracking 
(BVT) 
improved 
post dialysis 
BP in 
hypotensive 
prone 
patients and 
whether BVT 
is effective in 
reducing post 
treatment 
weight.  
BVT is 
associated 
with better 
intradialytic 
hemodyna
mic 
stability (p 
<0.01) and 
higher 
systolic BP 
after HD 
(BVM with 
constant 
weight vs 
SHD p 
=0.07, 
BVM with 
reduction in 
weight vs 
SHD p = 
0.15) 
compared 
to standard 
HD. 
However, it 
is not able 
to lower 
post HD 
weight (p 
>0.05).  
 
BVT is 
effective in 
reducing 
IDH and 
increase 
systolic BP 
up to 16 
hours post 
HD.  
S: Defined 
IDH 
treatment 
interventions
, defined 
IDH (not 
defined as 
KDOQI 
guidelines), 
and drew 
pre- and 
post- sodium 
level labs.  
L: Small 
sample size, 
adjusts both 
dialysate 
conductivity 
(adjusts 
sodium) and 
BVT guided 
UF.  
Manipulati
ve variable 
was BVT a 
form of 
BVM 
technology
.  
Level 
III 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Biofeedbac
k controlled 
hemodialysi
s (BF-HD) 
reduces 
symptoms 
and 
increases 
both 
hemodynam
ic 
tolerability 
and dialysis 
adequacy in 
non-
hypotension 
prone stable 
patients. 
McIntyre 
C.W., 
Lambie 
S.H., and  
Fluck R.J. 
(2003) 
Prospectiv
e study  
n=15 
Mean age 66, 14 males and 
one female. 
Inclusion criteria: on HD 
for >6 months at the 
beginning of BF-HD, 
dialyzing through an 
established arteriovenous 
fistula, considered stable 
based on previous history, 
prior to transfer to minimal 
care facility.  Patients HD 
treatments complicated by 
systolic BP >40% (IDH) 
was 0.9 (0-3) 
episodes/patient/3- week 
period and significant 
symptoms related to IDH 
was 1 (0-4) 
episodes/patient/3-week 
period, and no patient had 
interdialytic weight gains 
>4kg.  
Exclusion criteria: None 
mentioned.  
Setting: 4 station minimal 
care dialysis facility within 
in the author’s main unit 
(UK).  
Evaluate the 
use of BF-
HD in 
patients that 
are 
considered 
stable 
(representativ
e of most 
chronic HD 
patients). 
Investigate 
BVM and its 
effect on 
tolerability, 
blood 
pressure, 
interdialytic 
weight gain, 
and urea 
clearance. 
BF-HD can 
improve 
hemodyna
mic 
tolerability 
(p <0.001) 
and 
morbidity 
(p <0.001). 
In addition, 
decrease 
interdialytic 
weight gain 
(p = 0.009) 
and 
improve 
urea 
clearance 
(single pool 
p = 0.03, 
equilibrated 
p <0.01). . 
Also, 
decreases 
the amount 
of nursing 
intervention
s for IDH.  
 
BF-HD 
may 
possess 
benefits for 
a larger 
dialysis 
population 
group than 
existing 
data 
suggest.  
S: 
prescription 
optimization 
period, 
defined IDH, 
no alteration 
in blood 
flow rate, 
dialyzer type 
or size, or 
treatment 
times; and 
no alteration 
in dietary 
sodium 
intake.   
L: Small 
sample size, 
definition of 
IDH was not 
in 
accordance 
with KDOQI 
guidelines, 
changed UF 
and dialysate 
conductivity, 
more males 
than females 
in sample, 
and non-
pone IDH 
population.   
Manipulati
ve variable 
is BF-HD 
is BVM 
technology
.  
Level II 
  
51 
 
     
Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Blood 
volume-
controlled 
hemodialysi
s in 
hypotension
-prone 
patients: a 
randomized
, 
multicenter 
controlled 
trial 
Santoro 
A., 
Mancini 
E., Basile 
C., 
Amoroso 
L.., Di 
Giulio S., 
Usberti 
M., 
Colasanti 
G., 
Verzetti 
G., Rocco 
A., 
Imbasciati, 
Panzetta 
G., 
Bolzani R., 
Grandi F., 
and 
Polacchini 
M. (2002) 
Multicente
r, 
prospectiv
e, 
randomize
d, 
crossover 
study  
n=36 
Mean age 67.1, mean time 
on dialysis 41.8 months, 
sex M/F 14/18, hgb 10.3 
g/dL, hct 31.6, serum 
albumin 3.9 g/dL, cause of 
ESRD: glomerulonephritis 
18.8%, interstitial 
nephropathy 15.6%, 
nephroangiosclerosis 25%, 
PKD 18.8%, Diabetes 
18.8%.  
Inclusion criteria: HD 3 
times/week, treatment time 
≥180 minutes, stable 
clinical conditions with 
residual diuresis 
≤400mL/day, stable hgb or 
hct, a mean interdialytic 
weight gain ≥1.5kg, 
reduced hemodynamic 
stability during HD (one 
episode of acute IDH in 20-
80% of dialysis) in the last 
two months prior to the 
start of the study, and have 
one of the following 
comorbid conditions: 
cardiac disease, DM I/II, 
and arterial hypertension 
(already present and 
diagnosed for at least 6 
months).  
Compare 
blood volume 
tracking 
system to 
standard 
bicarb 
dialysis in 
respect to 
improvement 
in tolerability 
in a large 
number of 
IDH prone 
patients. 
Secondly, 
identify 
patient 
parameters to 
help 
recognize 
which 
patients draw 
the most 
benefits from 
continuous 
and 
automatic 
BVM.  
BVM 
improved 
intradialytic 
cardiac 
stability (p 
= 0.004) 
with 
improveme
nts in 
interdialytic 
symptoms 
(p <0.001). 
Population 
that seemed 
to respond 
better to 
this 
treatment 
were patient 
with an 
increased 
risk for 
IDH during 
standard 
HD and 
non-
hypotensive 
pre-dialysis 
BP.  
 
 
 
This is the 
first step in 
a 
physiologic
al dialysis 
where 
treatment 
parameters 
are 
dynamically 
changed by 
the delivery 
system 
incorporatin
g adaptive 
and logic 
controls.  
S: Defined 
IDH, 
population 
predisposed 
to IDH, 
multicenter 
study, pre 
and post 
sodium level 
draws once a 
week.  
L: Small 
sample size 
compared to 
statistical 
sample 
analysis, 32 
subjects 
included in 
statistical 
analysis, 
Kt/V is 
estimated, 
BV guided 
conductivity, 
and IDH was 
not defined 
within the 
parameters 
of KDOQI 
guidelines.  
 
  
Manipulati
ve variable 
is BVM 
technology
.  
Level I  
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
Exclusion criteria: The 
presence of a persistent 
intradialytic cardiac 
instability (IDH occurred in 
>80% of treatments).  
Setting: 10 HD centers 
(Italy). 
Efficacy 
and safety 
of 
haemodialy
sis 
treatment 
with the 
Hemocontr
ol 
biofeedback 
system: a 
prospective 
medium-
term study 
Basile C., 
Giordano 
R., 
Vernaglion
e L.., 
Montanaro 
A., De 
Maio P., 
De Padova 
F., 
Marangi 
A.L., Di 
Marco L.., 
Santese D., 
Semeraro 
A., and 
Ligorio 
V.A. 
(2001) 
Multicente
r, 
prospectiv
e, 
randomize
d cross 
over study  
n= 35 
7 males and 12 females, 
mean age 64.5, mean time 
on dialysis 80.5 months, 
and affected by different 
nephropathies including 
two with DM.  
Inclusion criteria: 
Maintenance standard 
bicarb treatment for at least 
6 months and hemodynamic 
instability (≥20% HD 
sessions complicated by 
symptomatic IDH).  
Exclusion criteria: None 
described.  
Setting: 10 Italian dialysis 
units.  
Assess 
whether 
bicarbonate 
treatment 
equipped 
with HBS 
was able to 
decrease 
cardiovascula
r instability 
and patient 
morbidity 
compared 
with standard 
bicarbonate 
treatment. 
Compare the 
efficacy and 
safety of 
HBS with 
that of 
standard 
bicarbonate 
treatment in 
the medium 
term. 
HBS is 
effective in 
reducing 
IDH and 
other intra- 
and inter 
dialytic 
symptoms 
(p <0.02). 
HBS is an 
effective 
treatment in 
decreasing 
hypovolemi
a related 
morbidity 
than 
standard 
treatment. 
Also, it is a 
safe 
treatment 
for medium 
term 
because the 
results are 
attained 
without 
potential 
harmful 
changes in 
BP, weight, 
and serum 
sodium 
levels.  
S: Defined 
IDH, 
patients 
wrote down 
symptoms 
pre, intra and 
post HD 
(symptoms 
were rated 
on a 0-10 
scale), blood 
draws in the 
beginning of 
each month 
(ABGs, 
serum urea 
nitrogen, 
creatinine, 
calcium, 
sodium, 
potassium, 
phosphate, 
uric acid, 
hemoglobin, 
and 
hematocrit), 
HBS is the 
manipulati
ve variable 
(this is a 
form of 
BVM 
technology
).  
Level I  
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
nursing staff 
recorded 
IDH and 
muscle 
cramps, BP 
was taken in 
supine 
position, no 
eating or 
drinking was 
permitted 
during 
treatment,   
L: Kt/V was 
estimated 
not 
confirmed 
by blood 
draw, two 
studies the 
medium 
study lacked 
a time 
control 
group while 
the short-
term study 
included an 
on/off 
treatment 
schedule, it 
did not 
identify 
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Study 
Name  
Authors 
 
Design  Sample Size, Participants, 
and Settings 
Aim Key 
Findings 
Suggested 
Interventio
ns 
Strengths 
(S) & 
Limitations 
(L)  
 
Relevance  
Level 
of 
Eviden
ce  
asymptomati
c IDH, and 
HBS also 
changed 
dialysate 
conductivity.  
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Reducing 
symptoms 
during 
hemodialysis 
by 
continuously 
monitoring 
the 
hematocrit. 
Steuer 
R.R., 
Leypoldt 
J.K., 
Cheung 
A.K., 
Senekjian 
H.O., and 
Conis 
J.M. 
(1996) 
Single 
sample non-
randomized 
control trial  
n=6  
Sample no described.  
Inclusion criteria: 
Dialysis staff determined 
based on experience 
which patients were IDH 
prone.  
Exclusion criteria: None 
described.  
Setting: University of 
Utah affiliated 
Bonneville Dialysis 
Unit.  
Exploit 
critical 
hematocrit 
threshold to 
design 
strategies to 
may reduce 
intradialytic 
morbidity 
without 
changing 
treatment 
times or 
target 
volume 
removal.  
There are 
other 
symptoms 
correlated 
with 
hypovolemia 
that are not 
reflected by 
BP. BVM 
appears to be 
more useful 
than BP 
monitoring 
in predicting 
and 
preventing 
hypovolemia 
induced 
morbidity (p 
0.02). 
Hematocrit 
threshold is a 
valid concept 
that shows a 
two-fold 
reduction in 
hypovolemic 
symptoms 
without 
extending 
treatment 
time or 
reducing 
target fluid 
removal. 
Large scale 
studies are 
needed to 
determine 
what patient 
population 
would most 
benefit from 
this 
technique.  
S: Defined 
IDH, no blood 
transfusions 
given, and 
used 
intradialytic 
symptoms as 
end points for 
intradialytic 
morbidity 
without 
changes in BP 
improved 
standard 
deviations and 
hematocrit 
thresholds.   
L: Small 
sample size, 
sodium 
concentration 
fluctuated 
during 
treatment, 
lacked wash 
out period, did 
not included 
asymptomatic 
IDH, and did 
not include 
various other 
symptoms that 
occurred 
during HD. 
Sample not 
described.   
Crit-lines 
are a form 
of BVM 
technology.  
Level 
III 
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